Third Harmonic Bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. CEO Natalie Holles will engage in fireside chats at the following events:

• Morgan Stanley 22nd Healthcare Conference on September 4, 2024, at 9:15 a.m. ET
• Stifel 2024 Virtual Immunology and Inflammation Summit on September 18, 2024, at 9:00 a.m. ET

The company, which focuses on developing innovative treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide live audio webcasts of these presentations. These webcasts will be accessible through the Investors & Media section of Third Harmonic Bio's website, with archived replays available for 90 days after each event.

News Market Reaction

-5.00%

1 alert

-5.00% News Effect

On the day this news was published, THRD declined 5.00%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the following upcoming conferences:

• Morgan Stanley 22^nd Healthcare Conference on Wednesday, September 4, 2024, at 9:15 a.m. ET
• Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ET

A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.

About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.

Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com

FAQ

When is Third Harmonic Bio (THRD) participating in the Morgan Stanley Healthcare Conference?

Third Harmonic Bio (THRD) is participating in the Morgan Stanley 22nd Healthcare Conference on Wednesday, September 4, 2024, at 9:15 a.m. ET.

What is the date for Third Harmonic Bio's (THRD) presentation at the Stifel Virtual Immunology and Inflammation Summit?

Third Harmonic Bio (THRD) is presenting at the Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ET.

How long will the webcasts of Third Harmonic Bio's (THRD) investor conference presentations be available?

The archived replays of Third Harmonic Bio's (THRD) investor conference presentations will be accessible for 90 days following each event.

What therapeutic areas does Third Harmonic Bio (THRD) focus on?

Third Harmonic Bio (THRD) focuses on advancing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases.